Which medications have a low metabolic risk associated with their use?

The choice of Aripiprazole and Brexpiprazole is appropriate due to their relatively favorable metabolic profiles compared to other antipsychotic medications. Both of these medications are classified as atypical antipsychotics and have been associated with a lower incidence of weight gain and metabolic side effects, such as dyslipidemia and insulin resistance.

Aripiprazole acts as a partial agonist at dopamine D2 receptors and has a unique action that contributes to a more balanced neurotransmitter modulation. This mechanism is thought to mitigate some of the weight gain risks typically seen with other antipsychotic agents. Similarly, Brexpiprazole, which is a derivative of Aripiprazole, also shows a low propensity for metabolic side effects. Clinical studies have demonstrated that patients taking these medications tend to maintain or have a minimal change in weight.

In contrast, the other choices include antipsychotic medications that are more commonly associated with metabolic risks. For instance, Iloperidone and Lurasidone, while better than some older antipsychotics, still carry some level of risk for metabolic side effects. Similarly, Risperidone and Olanzapine are well-documented for their considerable risk of weight gain